Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

Symptoms relating to spasticity are common in multiple sclerosis (MS) and can be difficult to treat. We have investigated the efficacy, safety and tolerability of a standardized oromucosal whole plant cannabis‐based medicine (CBM) containing Δ‐9 tetrahydrocannabinol (THC) and cannabidiol (CBD), upon spasticity in MS. A total of 189 subjects with definite MS and spasticity were randomized to receive daily doses of active preparation (n = 124) or placebo (n = 65) in a double blind study over 6 weeks. The primary endpoint was the change in a daily subject‐recorded Numerical Rating Scale of spasticity. Secondary endpoints included a measure of spasticity (Ashworth Score) and a subjective measure of spasm. The primary efficacy analysis on the intention to treat (ITT) population (n = 184) showed the active preparation to be significantly superior (P = 0.048). Secondary efficacy measures were all in favour of active preparation but did not achieve statistical significance. The responder analysis favoured active preparation, 40% of subjects achieved >30% benefit (P = 0.014). Eight withdrawals were attributed to adverse events (AEs); six were on active preparation and two on placebo. We conclude that this CBM may represent a useful new agent for treatment of the symptomatic relief of spasticity in MS.

[1]  P. Robson,et al.  The Medicinal Uses of Cannabis and Cannabinoids , 2008 .

[2]  R. Pertwee.  Cannabinoids and Multiple Sclerosis , 2007, Molecular Neurobiology.

[3]  A. Thompson,et al.  Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  T. Friede,et al.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis , 2005, Neurology.

[5]  T. Vollmer,et al.  Prevalence and treatment of spasticity reported by multiple sclerosis patients , 2004, Multiple sclerosis.

[6]  C. Polman,et al.  The therapeutic value of cannabinoids in MS: real or imaginary? , 2004, Multiple sclerosis.

[7]  D. Wade,et al.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.

[8]  C. Vaney,et al.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study , 2004, Multiple sclerosis.

[9]  K. Berkley,et al.  An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis , 2004, Multiple sclerosis.

[10]  P. Robson,et al.  A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215) , 2004 .

[11]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial , 2003, The Lancet.

[12]  L. Metz,et al.  Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? , 2003, The Lancet.

[13]  C. Young,et al.  Anti-spasticity agents for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.

[14]  R. Stebbins,et al.  Cannabis Use as Described by People with Multiple Sclerosis , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  P. Tappenden,et al.  A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. , 2002, Health technology assessment.

[16]  D. Altman,et al.  Validating scales and indexes , 2002, BMJ : British Medical Journal.

[17]  J. Farrar,et al.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale , 2001, PAIN.

[18]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[19]  Richard W. Bohannon,et al.  Criterion validity of lower extremity Motricity Index scores , 2000, Clinical rehabilitation.

[20]  H Rodgers,et al.  A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity , 1999, Clinical rehabilitation.

[21]  D. Wade,et al.  Assessing motor impairment after stroke: a pilot reliability study. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[22]  G. Ellison,et al.  Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. , 1988, Advances in alcohol & substance abuse.

[23]  C. Ellenberger,et al.  Treatment of Human Spasticity with Δ9‐Tetrahydrocannabinol , 1981 .

[24]  A. Frotzler,et al.  Relationship between self- and clinically rated spasticity in spinal cord injury. , 2006, Archives of physical medicine and rehabilitation.

[25]  H. Rothgang,et al.  [The National Institute for Clinical Excellence (NICE)]. , 2004, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[26]  Ethan B. Russo.  Safety, tolerability, and efficacy of orally administered cannabinoids in MS. , 2003, Neurology.

[27]  Douglas G Altman,et al.  Statistics Notes: Validating scales and indexes. , 2002, BMJ.

[28]  A. Zuardi,et al.  Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. , 1982, Psychopharmacology.

[29]  C. Ellenberger,et al.  Treatment of human spasticity with delta 9-tetrahydrocannabinol. , 1981, Journal of clinical pharmacology.

[30]  D. Petro.  Marihuana as a therapeutic agent for muscle spasm or spasticity. , 1980, Psychosomatics.

[31]  T. Bisogno,et al.  Endocannabinoids control spasticity in a multiple sclerosis model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.